Metraipolis › archive › dc_e50a146af9ea
Assessment of the risk of discontinuation of tenofovir disoproxil fumarate after delivery and the benefit of continued treatment in patients with immune… — Europe PMC PMID:41282013
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41282013
- DOI
- 10.3389/fmed.2025.1597664
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T17:57:59.945Z
- SHA-256 of the archived text
ab9575e69a11e5ec1c4d7e0960876dec002bf697cf6737283c699e018d019495- Stable URL of this page
https://metraipolis.com/documento/dc_e50a146af9ea
How to cite
Assessment of the risk of discontinuation of tenofovir disoproxil fumarate after delivery and the benefit of continued treatment in patients with immune… — Europe PMC PMID:41282013 — Europe PMC (en), https://europepmc.org/article/MED/41282013 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e50a146af9ea (Metraipolis archive dc_e50a146af9ea, sha256 ab9575e69a11e5ec1c4d7e0960876dec002bf697cf6737283c699e018d019495)
BibTeX
@misc{dce50a146af9ea,
title = {Assessment of the risk of discontinuation of tenofovir disoproxil fumarate after delivery and the benefit of continued treatment in patients with immune… — Europe PMC PMID:41282013},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41282013},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e50a146af9ea; sha256 ab9575e69a11e5ec1c4d7e0960876dec002bf697cf6737283c699e018d019495},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41282013. Agents can read the archived copy with the MCP tool read_document.